PubMed Health⌕ Search

Biomedical subjects

C Darlington

Publications and source records attributed to C Darlington.

7 recordsLinked to original sources

Unusual 2-aminopurine fluorescence from a complex of DNA and the EcoKI methyltransferase.

The methyltransferase, M.EcoKI, recognizes the DNA sequence 5'-AACNNNNNNGTGC-3' and methylates adenine at the underlined positions. DNA methylation has been shown by crystallography to occur via a base flipping mechanism and is believed to be a general mechanism for all methyltransferases. If no structure is available, the fluorescence of 2-aminopurine is often used as a signal for base flipping as it shows enhanced fluorescence when its environment is perturbed. We find that 2-aminopurine gives enhanced fluorescence emission not only when it is placed at the M.EcoKI methylation sites but also at a location adjacent to the target adenine. Thus it appears that 2-aminopurine fluorescence intensity is not a clear indicator of base flipping but is a more general measure of DNA distortion. Upon addition of the cofactor S-adenosyl-methionine to the M.EcoKI:DNA complex, the 2-aminopurine fluorescence changes to that of a new species showing excitation at 345 nm and emission at 450 nm. This change requires a fully active enzyme, the correct cofactor and the 2-aminopurine located at the methylation site. However, the new fluorescent species is not a covalently modified form of 2-aminopurine and we suggest that it represents a hitherto undetected physicochemical form of 2-aminopurine.

2-Aminopurine↗

Fampridine Acorda Therapeutics.

Fampridine (EL-970; 4-aminopyridine), a potassium channel blocker, is in phase II development by Acorda for the potential treatment of spinal cord injuries and multiple sclerosis (MS) [385529]. Originally, Elan was evaluating fampridine for the treatment of spinal cord injuries in collaboration with Acorda Therapeutics [243393]. The drug was licensed from Rush Medical Center and Elan holds worldwide rights with Rush to provide clinical and technical support. Elan has used its Intestinal Protective Drug Absorption System (IPDAS) drug delivery system to produce Neurelan, which is a controlled-release (twice daily) formulation of fampridine [223736]. However, it seems possible that production of Neurelan might be taken over by Acorda [381211]. Acorda completed preliminary phase II trials of the drug for spinal cord injury (SCI) in 1998 [303023]. In February 2000, the company predicted that it would begin the a late-stage phase II trial for chronic (long-term) SCI in the first quarter of 2000 [355696], [350955]. The trial, which will be double-blind, randomized and placebo-controlled, will enroll 90 people with chronic SCI at 10 US rehabilitation centers [355696]. As of July 2000, phase II studies for chronic SCI were underway and phase III studies are expected to begin in 2001 [376610]. Results presented at the EPHAR '99 congress showed that contractions induced by 4-AP in porcine coronary arteries, are likely to depend on the neuronal 5-HT, but not on the noradrenaline store in this tissue [334161].

4-Aminopyridine↗

Org 2766 prevents disruption of vestibular compensation by an NMDA receptor antagonist.

The adrenocorticotrophic hormone fragment 4-9 (ACTH-(4-9)) analog, Org 2766 has been shown to accelerate vestibular compensation. However, N-methyl-D-aspartate (NMDA) receptor antagonists disrupt the recovery process. When Org 2766 was administered at a dose of 20 nmol/kg every 4 h for 52 h, it prevented the disruption of compensation usually produced by a single 5 mg/kg i.p. injection of the NMDA receptor antagonist 3-([+]-2-carboxy-piperazin-4yl)-propyl-1-phosphonic acid (CPP). NMDA receptor antagonists and ACTH-like peptides may produce their effects on compensation by acting directly or indirectly at the same receptor complex.

Adrenocorticotropic Hormone↗